Department of Medicine

Medical School

Minnesota Glomerular Disease Program

Minnesota Glomerular

Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller

Mission

To provide patients with glomerular disease with expert, individualized care and access to clinical trials.

Covered Diseases

  • Any glomerular disease, including (but not limited to):
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous nephropathy
    • Minimal change disease 
    • IgA nephropathy
    • Immune complex mediated diseases
    • C3 Glomerulopathy
    • Fibrillary Glomerular Disease
    • Cryoglobulinemia
    • Anti-Glomerular Basement Membrane (anti-GBM) Disease
    • Alport Syndrome
    • Thin basement membrane disease
    • Vasculitis
    • Lupus Nephritis
  • For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

  • Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with glomerular disease.

Our Team

Physicians

Clinical & Translational Research Team

Ongoing Clinical Trials

MEMBRANOUS NEPHROPATHY

Phase 2 Trial

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase 3 Trial
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Principal Investigator
Michelle Rheault, MD

Study Coordinators

Amy Hanson, CCRC
amhanson@umn.edu

CLINICAL TRIAL

IGA NEPHROPATHY

Phase 3 Trial

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

Principal Investigator
Surabhi Thakar, MD

Co-Investigator
Katti Woerner, MD

Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 3 Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

CONTACT

General Inquiries